CDK2 subtype, specifically, received a great attention as a therapeutic target for cancer treatment due to its key role in several cellular processes upon complexation with its activating cognate, cyclin A or E, in addition, dysregulation of CDK2 or its cyclin partners was detected in various cancers such as ovarian, lung, pancreatic carcinomas, melanoma as well as breast cancer 23–27,.34–37. Here, CCNA2 is linked to cancer.